We reported previously a model of polyglutamine repeat disorders with insertion of 146 CAG repeats into the murine hypoxanthine phosphoribosyl transferase locus (Hprt (CAG)146 ; Ordway et al. [1997] Cell 91:753-763), which does not normally contain polyglutamine repeats. These mice develop an adult-onset neurologic phenotype of incoordination, involuntary limb clasping, seizures, and premature death. Histologic analysis demonstrates widespread ubiquinated neuronal intranuclear inclusions (NIIs). We now report characterization of the age of onset of behavioral abnormalities, correlated with the time course of occurrence of NIIs in several brain regions, and the occurrence of NIIs in non-neuronal tissues. Onset of behavioral abnormalities occurred at approximately 22 weeks of age. There was variable time course of expression of NIIs in several brain regions. Assessment of several non-neuronal tissues revealed nuclear inclusions in hepatocytes and choroid plexus epithelium. ␥-Aminobutyric acid (GABA)/benzodiazepine receptors, dopamine D1-like and D2-like receptors, and type 2 vesicular monoamine transporter (VMAT2) binding sites were assayed before and after the onset of behavioral abnormalities. GABA/ benzodiazepine receptors were unchanged either before or after the onset of behavioral abnormalities in any region analyzed, whereas striatal D1-like and D2-like receptors were diminished after but not before the onset of symptoms. Dorsal striatal VMAT2 binding sites were decreased before the onset of behavioral changes. Mitochondrial electron transport chain components were assayed with histochemical methods before and after the onset of behavioral changes. There was no change in behaviorally presymptomatic or symptomatic animals. Hprt (CAG)146 mice did not exhibit increased susceptibility to the mitochondrial toxin 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Hprt (CAG)146 mice are a useful model for studying polyglutamine repeat disorders.
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Polyglutamine repeat diseases share a common histopathologic hallmark; intraneuronal aggregates of proteolytic fragments of the pathogenic protein containing the polyQ domain Paulson et al., 1997; Becher et al., 1998) . The inclusions are often ubiquinated and contain other proteins. Aggregates occur within the nucleus (neuronal intranuclear inclusions, NIIs) and the cytoplasm. There is good evidence that intranuclear localization of polyQ-containing fragments is a key step in the pathogenesis of neurodegeneration, but the specific pathogenic role of NIIs is unclear (Klement et al., 1998; Saudou et al., 1998; Kim et al., 1999; Cummings et al., 1999) .
Ultrastructural evidence of NIIs in HD was published approximately 30 years ago, but their significance was unappreciated until their rediscovery in murine genetic models of HD (Tellez-Nagel et al., 1974; Mangiarini et al., 1996; Davies et al., 1997) . The rediscovery of NIIs emphasizes the importance of murine genetic models. Transgenic and knockin murine models of several CAG repeat disorders have been created that reproduce several aspects of the human diseases (Burright et al., 1995; Ikeda et al., 1996; Mangiarini et al., 1996; Reddy et al., 1998; Hodgson et al., 1999; Levine et al., 1999; Sato et al., 1999; Schilling et al., 1999; Shelbourne et al., 1999; Huynh et al., 2000; Wheeler et al., 2000; La Spada et al., 2001; Lin et al., 2001; Katsuno et al., 2002; Watase et al., 2002; Yoo et al., 2003) .
The common features of these diseases suggest common mechanisms of pathology driven by the expanded CAG repeats, modified possibly by expression patterns and surrounding sequences of the affected proteins. This inference predicts that expanded CAG repeats would be neurotoxic in any appropriately expressed "carrier" gene. We evaluated this prediction by developing a mouse line with 146 CAG repeats in the hypoxanthine phosphoribosyl transferase locus, (Hprt (CAG)146 ), a gene that does not normally include CAG repeats. This line has adult-onset neurologic abnormalities, shortened life span, and widespread expression of NIIs, confirming the primary importance of the expanded CAG repeat domains (Ordway et al., 1997) . Hprt is inactivated in these animals. Because Hprt inactivation in mice is devoid largely of major consequences, these results are consistent with the gain of function concept (Jinnah et al., 1991 (Jinnah et al., , 1992 (Jinnah et al., , 1994 .
We report additional data on this line, including more precise determination of the age of onset of the behavioral changes, the time course of development of NIIs in mice characterized for behavioral abnormalities, the pattern of alterations in neurotransmitter markers, the integrity of mitochondrial electron transport chain markers, and susceptibility to the mitochodrial toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).
MATERIALS AND METHODS Mice
The Hprt (CAG)146 knockin mouse line generated by gene targeting in mouse embryonic stem (ES) cells (Ordway et al., 1997) was used in all experiments. These studies were carried out on hemizygous males and homozygous females derived from breeding of heterozygous females with hemizygous males. Hprt is an X-linked locus and females express one copy of the locus due to X-inactivation. Offspring from these matings were genotyped by polymerase chain reaction using primers flanking the repeat region as described previously (Ordway et al., 1997) . Initial work indicated no significant differences in the pathology of male and female mutants. Control animals were similarly genetargeted mice with 70 CAG repeats inserted in the Hprt locus (Hprt (CAG)70 ). These mice do not develop behavioral changes or NIIs and have normal life spans (Ordway et al., 1999) .
Behavioral analysis
Twenty seven Hprt (CAG)146 mice, 15 to 24 weeks old, were analyzed to more precisely define the age of onset of behavioral abnormalities. Animals younger than 15 weeks never showed behavioral abnormalities. Control animals were 12 Hprt (CAG)70 mice, aged 24 to 64 weeks. Animals were housed separately for behavioral analysis. Cages were placed in a brightly lit laminar flow hood and cage tops removed. Normal mice will actively move about the cage under these conditions. Each mouse was scored as active if it roamed from its initial position or reared within 30 seconds of cage lid removal. Mice were then held suspended by the tail for 1 minute. Normal mice flail, extend limbs, and attempt to escape by climbing onto the tester's finger. Clasping of the fore-or hindlimbs is abnormal and was scored as present or absent. Mice able to climb onto the tester's finger within 1 minute were scored as escaping; those unable to escape were scored as abnormal. For rotarod analysis, mice were placed on a 4 cm diameter rotarod turning at 2.5 rpm 30 cm above a padded cage bottom (Ugo Basile, Comeria, Italy). Mice were scored as falling or not falling within a 60-second trial. Animals underwent 10 trials on 10 consecutive days. If a test was abnormal on 20% of trials, that animal was scored as abnormal on that test. If a seizure was witnessed during any trials, that animal was scored as having epilepsy. Animals were assigned a point for each abnormality on each test-diminished spontaneous activity, clasping, in-ability to escape from suspension, falling from the rotarod within 60 sec, and presence of epilepsy-for a cumulative behavioral abnormality score with a possible total of 5 points. The higher the score, the greater number of behavioral abnormalities. Statistical analysis was performed between group behavioral abnormality scores with the nonparametric Mann-Whitney U test using the VassarStats program (http://faculty.vassar.edu/lowry/ VassarStats.html).
Immunohistochemistry and quantification of NIIs
Mice were deeply anesthetized by intraperitoneal injection of Avertin (Aldrich, 0.4 mg/g i.p.) and perfused through the heart with approximately 100 ml of 0.1 M phosphate buffer (PB, pH 7.4) followed by approximately 100 ml of 4% paraformaldehyde in PB. Organs were removed, post-fixed overnight in 4% paraformaldehyde in PB and cryoprotected in sucrose/PB (up to 20% sucrose). Frozen brains were cut into 40-m sections in the horizontal plane. Sections were sequentially collected in 1 in 5 series so that each group contained one section every 200 m throughout the brain. Heart, liver, lung, kidney, spleen, testes, and skeletal muscle were processed similarly. Tissue sections were stained with rabbit polyclonal antiserum against ubiquitin (1:250 or 1:1,000 dilution; Dako) overnight at 4°C. Hprt immunoreactivity was visualized with a rabbit polyclonal antipeptide antisera directed against amino acids 7-17 of Hprt. The antiserum identified a single appropriate band on Western blots. For immunohistochemistry, both 1:500 and 1:2,000 dilutions were used and gave identical results. Primary antisera were diluted in PB, 0.3% Triton X-100, and 1.5% blocking serum. Processing was completed with the ABC method using Vectastain Elite kits (Vector Laboratories, Temecula, CA). Detection was performed by using a diaminobenzidine (DAB) substrate and NiCl 2 according to the manufacturer's recommended protocol (Vector Laboratories). Sections were dehydrated in graded alcohols and xylenes and mounted on gelatin-coated slides, and coverslips were affixed with Permount (Fisher, Pittsburgh, PA). Sections were viewed on a Nikon Eclipse E800 microscope. Adjacent series of sections were stained with 0.5% cresyl violet.
For quantification, ubiquitin-immunostained sections were used. By approximately 30 weeks of age, NIIs were found in virtually all regions examined. Regions were selected for quantification on the basis of relevance to human pathology (striatum, cerebellar cortex), early occurrence of NIIs (parabrachial nucleus), late occurrence of NIIs (globus pallidus), and to provide a representative sampling of other regions (frontal cortex, hippocampal formation, superior colliculus). NIIs were visualized by light microscopy at 800ϫ and counted by using an ocular grid. To provide approximate frequencies of NIIs, the number of NIIs counted was divided by the number of cresyl violet-stained neurons in fields from the same areas of adjacent cresyl violet-stained sections. Cresyl violet-stained neurons were distinguished from glia by characteristic nuclear and nucleolar morphology. At least five fields were counted per brain region per brain. Brains were scored as lacking NIIs only after thoroughly scanning all sections within a group that included sections at 200-m intervals throughout the brain. Parallel confirmatory experiments were performed with an N-terminal Hprt antiserum.
Receptor autoradiography

Hprt
(CAG)146 and control mice of various ages were killed by decapitation, and brains were extracted from the cranial vault, coated with Shandon-Lipshaw embedding matrix, and frozen in isopentane cooled by liquid N 2 . Brains were stored at Ϫ70°C until time of sectioning. Brains were warmed to Ϫ20°C, and 12-sections were cut on a cryostat and thaw-mounted onto gelatin-coated slides and stored at Ϫ70°C.
Receptor autoradiography was performed as described previously (Richfield et al., 1989; Higgins and Greenamyre, 1996; Suzuki et al., 2001) . To label type 2 vesicular monoamine transporter (VMAT2) binding sites, slides were prewashed for 5 minutes at room temperature (RT) in KBS-ethylenediaminetetraacetic acid buffer (pH 8.0), then incubated with 10 nM [ 3 H]methoxytetrabenazine (specific activity 82 Ci/mmol). Tetrabenazine (10 M) was added to the ligand buffer to determine nonspecific binding. After incubation, sections were rinsed twice for 2 minutes in cold assay buffer, dipped in cold distilled water, and dried under cool air.
Assays for D1 and D2 dopamine receptors used a 25 mM Tris buffer (pH 7.2) with 100 mM NaCl, 1 mM MgCl 2 , 1 M pargyline and 0.001% ascorbic acid. For D1 receptors, slides were incubated with 0.55 nM [
3 H]SCH23390 (specific activity 89 Ci/mmol) for 2.5 hours. Nonspecific binding was determined in the presence of 1 M cisflupentixol. For D2 receptors, slides were incubated in 0.75 nM [
3 H]spiperone (specific activity 96 Ci/mmol) with 100 nM mianserin for 2.5 hours. Nonspecific binding was defined in the presence of 50 M dopamine. After incubation, slides were rinsed in cold incubation buffer for 10 minutes, dipped in distilled water, and dried under cool air. Slides for ␥-aminobutyric acid (GABA)/benzodiazepine receptor assays were prewashed for 30 minutes in cold assay buffer (50 mM Tris-citrate buffer, pH 7.2), air-dried, and incubated with 5 nM [ 3 H]flunitrazepam (specific activity 85 Ci/mmol) for 30 minutes at 4°C. Nonspecific binding was determined in the presence of 2 M clonazepam in the ligand buffer. Sections were rinsed twice for 5 minutes in cold buffer and dried under warm air. Binding to complex I of the electron transport chain was examined by using 5 nM [ 3 H]dihydroxyrotenone (DHR; specific activity 60 Ci/mmol) in 50 mM Tris-HCl buffer, 1% bovine serum albumin (pH 7.6). Sections were incubated in ligand buffer for 2 hours at RT. Nonspecific binding was assessed by using 10 M rotenone. Slides were rinsed in RT incubation buffer for 1 hour, followed by two 5-minute washes in 25 mM Tris-HCl (pH 7.6) and 15 seconds in distilled water, then dried under a stream of warm air.
Tritium-labeled slides were apposed to tritium-sensitive film (Hyperfilm 3 H or BioMax, Amersham) with calibrated radioactive standards and exposed for 2 to 5 weeks. Films were developed and analyzed by using a computer-based image analysis system (MCID, Imaging Research, St. Catharine's, Ontario, Canada). Image density corresponding to binding of tritiated ligand was converted to pmol/mg protein using the calibrated standards. Specific binding was determined by subtracting nonspecific from total binding. Results were analyzed by using the VassarStats program with a correlated t test.
Histochemistry
For cytochrome oxidase histochemistry, slides were incubated in 0.1 M HEPES buffer (pH 7.4) with 3.165 mM nickel ammonium sulfate, 117 mM sucrose, 16.15 M cytochrome C, and 2.778 mM DAB for 30 -45 minutes at 37°C. The sections were rinsed twice, 10 minutes each, in fresh HEPES buffer, dipped in distilled water, air-dried, dehydrated, and cover-slipped. For succinate dehydrogenase histochemistry, slides were incubated in 60 mM phosphate buffer (pH 7.0) with 0.04% nitro blue tetrazolium and 50 mM succinate for 45 minutes at 37°C. The sections were then soaked for 10 minutes in 4% paraformaldehyde in 50 mM Phosphate buffer (pH 7.0), rinsed in distilled water, dehydrated, and cover-slipped. Sections were analyzed by measuring optical density using a computer assisted MCID image analysis system (Imaging Research). Regional optical density was quantified using a uniform gray scale under uniform illumination conditions. Results were compared using a correlated t test with the VassarStats program.
MPTP lesions
Mice of varying ages and genotype were treated with 0, 20, or 40 mg/kg MPTP injected intraperitoneally in four divided doses given at 2-hour intervals. After 7 days, the animals were killed by decapitation. Groups included both male and female mice. Genders of mice were balanced within almost all groups, and there was no effect of gender on results. The forebrains were frozen and processed for autoradiography as described above.
Image preparation
Photomicrographs were prepared by photographing images with an Olympus BX-51 microscope equipped with SPOT-RT digital camera (Diagnostic Instruments, Sterling Heights, MI). Autoradiographic and histochemical images were captured with an MCID apparatus (Imaging Research). Images were imported into Photoshop 5.5 (Adobe, San Jose, CA) for adjustment of contrast, brightness, and sharpness.
RESULTS
Behavioral results
Hprt
(CAG)146 mice began to manifest significant behavioral changes at approximately 22 weeks of age. To confirm this impression, Hprt (CAG)146 mice were divided into two groups; 15 to 21 weeks old (n ϭ 15) and 22 to 24 weeks old (n ϭ 11), and intergroup differences in cumulative behavioral abnormality scores (summation of all individual behavioral tests scored as normal or abnormal; see Materials and Methods section above) assessed with the nonparametric Mann-Whitney U test (Fig. 1) . For the 15-to 21-week group, the mean rank was 8.7. For the 22-to 24-month group, mean rank was 20. This difference is significant (P Ͻ 0.0002; two-tailed test). The 22-to 24-week group was compared also with a group of Hprt (CAG)70 control mice; 23 to 24 weeks old (n ϭ 6), 26 to 29 weeks old (n ϭ 2), and 60 to 64 weeks old (n ϭ 4); total n ϭ 12. The mean rank of Hprt (CAG) (Ordway et al., 1997 (Ordway et al., , 1999 .
Time course of occurrence of NIIs
NII occurrence was surveyed with ubiquitin immunohistochemistry in Hprt (CAG)146 mice 15 to 18 weeks old, 20 to 26 weeks old, 32 to 38 weeks old, and 40 to 46 weeks old (n ϭ 3-4 for each group). Assessing NII occurrence in older animals is difficult because of steeply rising mortality after 40 weeks. NII burden was assessed by estimating the percentage of Nissl-stained neurons expressing NIIs. No ubiquitin immunoreactive NIIs were found in the 15-to 18-week age group (Table 1; Fig. 2 ). In older animals, NIIs were detectable in varying numbers in all regions surveyed. In the 20-to 26-month age group, NIIs were present in a substantial percentage of neurons in the parabrachial nucleus and frontal cortex, i.e., 58% and 37%, respectively. Moderate percentages of NIIs (Ͻ20% and Ͼ10%) were present in cerebellar Purkinje cells, substantia nigra pars compacta neurons, superior colliculus neurons, and inferior colliculus neurons. Less than 10% of neurons in the hippocampal formation, striatum, globus pallidus, or substantia nigra pars reticulata expressed NIIs. In the 32-to 38-week age group, the regional distribution and percentage of NIIs was similar to that found in the 20-to 26-week age group with the possible exception of parabrachial neurons where the percentage of NIIcontaining neurons rose to 72%. In the 40-to 46-week age group, all regions exhibited abundant NIIs. Percentage of NIIs rose to 85% in the parabrachial nucleus and exceeded 60% in the frontal cortex, substantia nigra pars compacta, cerebellar Purkinje cells, and hippocampal formation. Percentage of NIIs exceeded 50% in striatal neurons, superior collicular neurons, and inferior collicular neurons. Even in regions with the lowest percentages of NIIs, the substantia nigra pars reticulata and the globus pallidus, percentage of neurons expressing NIIs was substantial, approximating 30%. Many regions displayed marked increases in control mice. The 22-to 24-week age group has higher mean behavioral scores than younger or control mice.
the percentage of neurons containing NIIs in the interval between the 32-to 38-week and 40-to46-week age groups. In the frontal cortex, cerebellar Purkinje cells, globus pallidus and substantia nigra pars compacta, there was a two-to threefold increase the percentage of neurons containing NIIs. In the remaining regions, the magnitude of the increase was greater, approximately 5-to 10-fold. Similar results were found with anti-Hprt antisera (Fig. 3) .
NIIs in non-central nervous system tissue
Non-central nervous system tissues were studied in two mutants, 30 and 46 weeks of age, and two wild-type mice. NIIs were found in hepatocytes but not in heart, lung, kidney, spleen, testes, or muscle (Fig. 4) . NIIs were seen also in choroid plexus epithelium (Fig. 4) .
Receptor binding studies
GABA/benzodiazepine receptor, D1-like receptor, D2-like receptor, and VMAT2 binding sites were assessed before and after the onset of behavioral abnormalities in Hprt (CAG)146 mice. Animals were assessed at approximately 16 weeks (n ϭ 4) and 45 weeks of age (n ϭ 7). These results were compared with results from older (approximately 55 week) Hprt (CAG)70 mice as described in the Fig. 5 ). D1-like receptor and D2-like receptor binding sites were significantly reduced in the striatal complex (striatum proper, nucleus accumbens, olfactory tubercle) of older (45 week) but not younger (16 week) Hprt (CAG)146 mice (Table 3 ; Fig. 5 ). In the substantia nigra, D1-like receptor binding sites were reduced similarly in older Hprt (CAG)146 mice. In the nigra, the great majority of D1-like receptor binding sites are on striatonigral terminals, and this finding is likely to reflect either reduced synthesis of D1-like receptors by striatal projection neurons or loss of striatal terminals within the substantia nigra. There was a trend toward increased substantia nigra D2-like receptor binding. Nigral D2-like receptors are expressed by substantia nigra dopaminergic neurons, and this increase could represent a concentrative effect of loss of surrounding neuropil due to degeneration of afferent striatal projection neuron terminals. VMAT2 binding, a measure of striatal dopaminergic terminals, was markedly reduced in the striatal complex and substantia nigra of older Hprt (CAG)146 mice (Table 3 ; Fig. 5 ). In the younger Hprt (CAG)146 mice, VMAT2 binding was reduced in the striatum proper, and there was a trend toward reduced VMAT2 binding in the nucleus accumbens, olfactory tubercle, and substantia nigra. Alterations in VMAT2 binding were the only changes we detected before the onset of behavioral changes or NII formation. Striatal VMAT2 binding is usually interpreted as a function of striatal dopamine terminal integrity but altered expression of VMAT2 is another possible explanation for this finding.
Mitochondrial electron transport chain activities
Complex I expression was assessed with [ 3 H]DHR binding, whereas Complex II/III and Complex IV activities were assessed histochemically with succinate dehydrogenase (SDH) and cytochrome oxidase (CyOx) 
Susceptibility to MPTP
To assess the vulnerability of Hprt (CAG)146 mice to mitochondrial impairment, we chose the neurotoxin MPTP. MPTP is a protoxin selective for dopaminergic neurons. MPTP is converted to MPP ϩ with the latter species selectively accumulated in dopaminergic neurons where it inhibits Complex I. We chose this approach because of ease of MPTP administration and ease of measurement of striatal dopamine terminal density with the VMAT2 ligand [ 3 H]MTBZ. Expression of NIIs within substantia nigra pars compacta neurons suggested that these neurons might be more vulnerable to mitochondrial impairment (Ordway et al., 1997) . Hprt (CAG)146 mice at varying ages (12-22 weeks, n ϭ 3-5; 27-32 weeks, n ϭ 5; 42-55 weeks, n ϭ 5-6) were evaluated after receiving 0 mg/kg, 20 mg/ kg, and 40 mg/kg of MPTP as described in the Materials and Methods section. The control animals were Hprt (CAG)70 mice. As described above, there was a decline in VMAT2 binding in the vehicle-treated Hprt 3 H]methoxytetrabenazine for dopamine terminals (Ϯ SEM) relative to specific ligand binding in aged Q70 animals. Specific binding determined by receptor autoradiography with conversion of film optical density to bound radioactivity using coexposed radioactive standards to generate a standard curve relating optical density to radioactivity. Bold values are significantly different from control values (P Ͻ 0.05). mice compared with Hprt (CAG)70 mice. In contrast to the results described above, differences between Hprt (CAG) 70 and Hprt (CAG)146 mice were not seen in the youngest mice. This finding is probably because this experiment included some younger animals (12 weeks) than the experiments described above (16 weeks). A total of 40 mg/kg MPTP treatment reduced striatal VMAT2 binding sites in both Hprt (CAG) 
DISCUSSION
Age of onset of behavioral abnormalities
We showed previously that Hprt (CAG)146 mice develop adult-onset behavioral abnormalities, have premature mortality, and exhibit abundant NIIs (Ordway et al., 1997) . Consistent with prior data, cumulative behavioral scores became abnormal at approximately 22 weeks of age. Repeat length is an important determinant of age of onset and penetrance (Stine et al., 1993; Rubinsztein et al., 1996) . Over some threshold, repeat number correlates inversely with age of onset of clinical disease (Huntington's Disease Collaborative Research Group, 1993; Rubinsztein et al., 1997) and accounts for approximately 50% of the variance in age of onset. In murine genetic models, repeat number and the amount of gene product have influenced age of onset (reviewed in Zoghbi and Botas, 2002) . In transgenic models, expanded CAG repeats in truncated constructs and/or high expression of transgenes are required to produce a phenotype. With knockin models of HD and SCA1, significant behavioral phenotypes develop only with CAG repeat expansions greater than those found typically in human patients (Lin et al., 2001; Menalled et al., 2002; Wheeler et al., 2002; Zoghbi and Botas, 2002; Watase et al., 2002) . The relatively short life span of mice may limit the opportunity to observe the effects of repeat lengths that are pathogenic in humans. Existing methods of behavioral evaluation may also be insufficiently robust to detect earlier changes.
The amount of mutant protein produced may also affect age of onset. The R6 transgenic HD lines developed by Bates' group vary in repeat number and levels of protein expression (Mangiarini et al., 1996) . Lines with higher repeat numbers and higher levels of protein expression have a more aggressive phenotype. In a transgenic yeast artificial chromosome (YAC) model of HD with 43 repeats, abnormalities are found only with supranormal expression levels of the mutant protein (Reddy et al., 1998) . In our knockin model of HD, mutant homozygous animals develop behavioral abnormalities at an earlier age than heterozygous animals (Lin et al., 2001) . Similar effects of homozygosity are found in a knockin model of SCA7 (Yoo et al., 2003) . Homozygous HD mutation carriers were reported originally to have clinical disease indistinguishable from heterozygotes, but recent data indicates that HD homozygotes have a more aggressive clinical course than heterozygotes (Wexler et al., 1987; Squitieri et al., 2003) . Earlier age of onset is reported in SCA3/MJD and DRPLA homozygotes (Sato et al., 1995; Sobue et al., 1996) . 
Time course of NII accumulation
The role of NIIs in neurodegeneration is controversial. By analogy with other forms of insoluble protein pathology, e.g., Lewy bodies and amyloid plaques, NIIs and cytoplasmic inclusions are suggested to be proximate causes of neurodegeneration in CAG repeat disorders Ross, 1997 Ross, , 2002 Scherzinger et al., 1997; Becher et al., 1998; Sisodia, 1998; Trojanowski and Lee, 2000) . Alternative interpretations of the role of NIIs are that they are epiphenomena or that they could be protective (Ordway et al., 1997; Sisodia, 1998; Ross, 2002; Zogbhi and Botas, 2002) .
NIIs were first visualized at approximately the same age as the development of behavioral abnormalities. In almost all regions studied, there was a marked increase in the percentage of neurons expressing NIIs in the 40 to 46 week age group, paralleling the ages at which mortality accelerates. This type of analysis cannot, however, establish causal relations between NIIs and behavioral abnormalities. We relied on ubiquitin immunohistochemistry to quantify the presence of NIIs. Aggregation of polyglutamine repeat-containing protein fragments may occur earlier than easily demonstrable ubiquination. In HD knockin mice, nuclear localization of huntingtin is an early event and emergence of huntingtin-immunoreactive NIIs precedes the development of ubiquitinimmunoreactive NIIs (Wheeler et al., 2000; TallaksenGreene et al., unpublished data) . With anti-Hprt antisera, we found a similar time course for NII emergence but our reliance on ubiquitin immunohistochemistry for quantification may underestimate the age of occurrence of NIIs and the apparent correlation with behavioral abnormalities may be spurious.
We found one region where evidence of neuronal dysfunction is dissociated from NII occurrence, the substantia nigra pars compacta (SNpc (Vander Borght et al., 1995a, b In vitro and in vivo experiments dissociated the toxic effects of expanded CAG repeat-containing intranuclear fragments from NII formation (Saudou et al., 1998; Klement et al., 1998; Kim et al., 1999; Cummings et al., 1999; Simeoni et al., 2000; Mastroberardino et al., 2002; Menalled et el., 2002; Watase et al., 2002) . In HD, there is not a good correlation between striatal neuron subpopulation expression of NIIs and the pattern of striatal neuron subpopulation degeneration Kuemmerle et al., 1999) . In SCA2, NIIs are expressed sparsely and without good correlation with the pattern of neurodegeneration (Huynh et al., 2000) . NIIs are probably not key mediators of pathogenesis in polyglutamine repeat disorders. NIIs could play a protective role by acting as a "sink" for toxic expanded CAG repeat-containing proteolytic fragments, and neurons able to form NIIs may be relatively protected against the effects of expanded CAG repeats. Oligomerization of polyglutamine-containing fragments, however, may be a key step in pathogenesis. Disruption of oligomerization with the azo-dye Congo Red, extends life span and reduces NII burden in R6/2 mice (Sanchez et al., 2003) . The role of NIIs could be multifactorial. In our data set, abundant NIIs were found in all regions examined around the period when mortality rates accelerated. NIIs may act as a protective sink in the early stages of neuronal injury but assume a pathogenic role later in the course of the disease.
Nuclear inclusions in non-neuronal tissues
We found nuclear inclusions in two non-neuronal cell populations: hepatocytes and choroid plexus epithelium. The relative lack of nuclear inclusions in non-neuronal cells is interesting in view of the widespread expression of Hprt. In R6/2 mice, which have diabetes, nuclear inclusions have been found in pancreatic islet cells, skeletal and cardiac muscle fibers, adrenal cortical cells, and myenteric plexus neurons (Hurlbert et al., 1999; Sathasivam et al., 1999) . It is unknown why NIIs are expressed preferentially in neurons and why neurons are particularly susceptible to the toxic effects of polyglutamine expansions. Neurons are unusually long lived postmitotic cells with an essentially zero rate of turnover in almost all brain regions. Even low rates of cell turnover might purge cells accumulating toxic polyglutamine-containing fragments. Some mitotically active cell populations express NIIs in R6/2 mice, and we did find nuclear inclusions in hepatocytes, a renewable cell type. Factors governing the expression of NIIs are likely to be complex, possibly including cell-specific differences in cell life span and metabolism of expanded polyglutamine-containing proteins.
Neurotransmitter marker changes and transcriptional dysregulation
We found differential effects on neurotransmitter markers in Hprt (CAG)146 mice. In both young and older Hprt (CAG)146 mice, there was no effect on expression of GABA/benzodiazepine receptor binding sites. Striatal D1-like and D2-like receptor binding site expression was diminished in older animals. Dorsal striatal VMAT2 binding was diminished significantly before the development of behavioral abnormalities and the occurrence of NIIs. The normal expression of GABA/benzodiazepine receptor binding sites argues against nonspecific loss of neurotransmitter marker binding sites due to neurodegeneration or nonspecific neuronal dysfunction. A similar result was described in the R6/2 model of HD (Cha et al., 1998; Reynolds et al., 1999) . Of interest, in this line, there is a similar decline in striatal dopamine terminal markers when markers of intrinsic striatal neurons are preserved (Reynolds et al., 1999; Hickey et al., 2002) . A likely explanation for this pattern of findings is selective loss of specific neurotransmitter markers due to transcriptional dysregulation (Luthi-Carter et al., 2000) .
Considerable evidence indicates that transcriptional dysregulation is not merely an epiphenomenon but central to the pathogenesis of neurodegenerative polyglutamine repeat disorders (Perutz et al., 1994; Boutell et al., 1999; Lin et al., 2000; Luthi-Carter et al., 2000; McCampbell et al., 2000 Holbert et al., 2001; Nucifora et al., 2001; Steffan et al., 2000 Steffan et al., , 2001 Chai et al., 2001 Chai et al., , 2002 Zhang et al., 2002; Dunah et al., 2002; Katsuno et al., 2002; Takeyama et al., 2002; Kegel et al., 2002) . Evidence from in vitro models and genetic models indicates that nuclear localization of expanded polyglutamine-containing polypeptides, possibly in the form of caspase-produced fragments, is a crucial step in pathogenesis (Goldberg et al., 1996; Wellington et al., 1998 Wellington et al., , 2002 Li et al., 2000; Kim et al., 2001) . For a dissenting view, however, see Dyer and McMurray (2001) . Expanded polyglutamine-containing polypeptides may aggregate with and sequester proteins involved in transcription (Boutell et al., 1999; McCampbell et al., 2000 McCampbell et al., , 2001 Holbert et al., 2001; Nucifora et al., 2001; Steffan et al., 2000; Chai et al., 2001 Chai et al., , 2002 Zhang et al., 2002; Dunah et al., 2002; Kegel et al., 2002) . Evidence from both human postmortem tissue and murine genetic models of HD, SCA1, and DRPLA indicates altered transcription in these diseases. Overexpression of sequestered transcriptionally active proteins reverses some of the effects of mutant huntingtin and atrophin in some model systems (Shimohata et al., 2000; Nucifora et al., 2001; Dunah et al., 2002) .
Transcriptional dysregulation is a plausible mechanism for explaining the regional and subregional specificity of neurodegeneration characteristic of polyglutamine diseases. Different populations of neurons express different complements of proteins active in transcription. Differential affinity of these proteins for the different expanded polyglutamine-containing protein fragments could explain differential regional and subregional neurodegeneration. This model is supported by results from a murine transgenic model of SCA7 where specific interference with the homeobox protein CRX is suggested to underlie retinal degeneration (La Spada et al., 2001 ). On the other hand, recent data from a knockin model of SCA7 contradicts this result (Yoo et al., 2003) .
Mitochondrial dysfunction
One creditable proximate cause of neurodegeneration in HD is excitotoxic injury. Acute N-methyl-D-aspartate (NMDA) receptor agonist striatal excitotoxic lesions are remarkable mimics of HD striatal pathology (Bazzett and Albin, 2001) . The most popular version of the excitotoxic hypothesis suggests that mitochondrial dysfunction increases neuronal susceptibility to NMDA receptormediated excitotoxic injury, so-called indirect excitotoxicity. Compounds that inhibit electron transport chain activity cause striatal lesions with many features of HD striatal pathology (Beal et al., 1993a, b; Greene and Greenamyre, 1995; Bazzett et al., 1995) . Several in vitro and in vivo studies describe mitochondrial dysfunction in HD or murine genetic models of HD (Jenkins et al., 1993; Browne et al., 1997; Sawa et al., 1999 , Tabrizi et al., 2000 Panov et al., 2002) . Guidetti et al. (2001) , however, did not find evidence of mitochondrial dysfunction in early postmortem HD material. The excitotoxic hypothesis predicts that murine genetic models of HD should exhibit increased susceptibility to mitochondrial toxins and/or NMDA agonists. Conflicting data exist on this point (Bogdanov et al., 1998; Hansson et al., 1999 Hansson et al., , 2001a Levine et al., 1999; Zeron et al., 2002) . A large clinical trial based on the indirect excitotoxicity hypothesis evaluated coenzyme Q10 (ubiquinone) as a mitochondrial function booster and the NMDA receptor antagonist remacemide (Huntington Study Group, 2001 ). There was no significant effect of either compound or the combination, although positive effects were seen in the R6/2 mouse model (Ferrante et al., 2002) .
Our data do not support the notion of mitochondrial dysfunction or increased susceptibility to mitochondrial toxins. The indirect excitotoxic hypothesis is plausible, but more evidence will be required to demonstrate its relevance to polyglutamine diseases.
Knockin vs. transgenic models
A theoretical advantage of this model and other "knockin" murine genetic models is that the expanded CAG repeat sequences are expressed in the context of their normal patterns of expression and regulatory genetic elements. Transgenic murine models can have multiple copies of transgenes, abnormal expression of polyglutamine repeat-containing proteins, and transgene expression is not regulated by sequences that normally control the pattern and level of expression. Transgenic models provide considerable insight into the general processes causing neurodegeneration but may not be close mimics of specific human CAG repeat disorders. Knockin models of HD, SCA1, and SCA7 exhibit somewhat different phenotypes than seen in transgenic lines (Burright et al., 1995; Mangiarini et al., 1996; La Spada et al., 2001; Lin et al., 2001; Watase et al., 2002; Wheeler et al., 2002; Yoo et al., 2003) . Whereas knockin lines require very long repeat numbers to produce a phenotype and the phenotype may be less aggressive than seen in transgenic lines, the patterns of pathology in knockin lines seem more similar to the human diseases. Important factors influencing phenotype in murine genetic models of HD are the number of repeats and the level of expression of mutant protein (see discussion above; Zoghbi and Botas, 2002) . Knockin lines may have the virtue of disentangling the roles of repeat number and level of protein expression. In knockin lines, levels of expression are comparable from line to line and differences in phenotype can be attributed to differences in repeat number.
If transcriptional dysregulation is at the heart of pathogenesis in polyglutamine disorders, then transgenic models with heightened levels of protein expression and nonphysiological distributions of gene expression may give misleading impressions of key factors in the pathogenesis of regional neurodegeneration. Comparison of CRX protein activity in transgenic and knockin models of SCA7 suggests that the diminished CRX protein activity found in the transgenic model may be an artifact of abnormally regulated expression of SCA7 mutant protein in the transgenic model (La Spada et al., 2001; Yoo et al., 2003) . Specific patterns of neurodegeneration may result from neuron subpopulation-specific interactions between expanded polyglutamine-containing protein fragments and transcriptionally active proteins, and these specific patterns of interaction may be distorted in transgenic models. At least with respect to HD, however, the more aggressive phenotypes exhibited by transgenic models are advantageous for some purposes. Evaluating potential therapies is easier in models with aggressive, early-onset phenotypes, and it will be prohibitively expensive to evaluate all potential therapies in HD knockin models. For all polyglutamine disorders, a combination of results from both transgenic and knockin models will likely be needed to investigate pathogenesis and evaluate potential therapies. Hprt (CAG)146 mice may be particularly useful in this context. The wide expression of neuronal pathology in this line allows study of polyglutamine toxicity in many brain
